Nexstim

Nexstim is a Finnish medical technology company committed to enhancing the quality of life for patients with significant unmet clinical needs. Founded in 2000 in Helsinki, Finland, Nexstim has a global presence and a mission to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

The company has developed SmartFocus®, a world-leading non-invasive brain stimulation technology which encompasses navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. This technology is utilized in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, FDA cleared for the treatment of major depressive disorder (MDD) in the United States, and CE marked for the treatment of major depression and chronic neuropathic pain in Europe.

Furthermore, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications, the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on Nasdaq First North Growth Market Finland. The company's last investment of €960.00K was a Post-IPO Equity investment on 18 June 2018 which was provided by Capricorn Venture Partners.